We recently published a list of 9 Stocks Jim Cramer Talked About. In this article, we are going to take a look at where ...

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $41.21, denoting a -1.44% change from the preceding trading day.

PFG Investments LLC lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 9.9% in the 4th quarter, ...

Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to ...

Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for CRISPR Therapeutics in a note issued to investors ...

In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), ...

In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against other stocks that Jim Cramer talked about. Jim Cramer, the host of Mad Money, reflected on ...

Below is Validea's guru fundamental report for CRISPR THERAPEUTICS AG (CRSP). Of the 22 guru strategies we follow, CRSP rates highest using our Value Investor model based on the published strategy ...

Vanguard Mid-Cap Value ETF features solid sector diversification. Learn why VOE's stock ranking and cash-flow valuation ...

Large-cap stocks are one of the most popular ways to invest in the market. These companies have the deepest pockets, and their businesses are more resilient than a typical small-cap. So large-caps ...

Morgan Stanley lowered the firm’s price target on Crispr Therapeutics (CRSP) to $30 from $45 and keeps an Underweight rating on the shares. The ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...